文献速递临床试验与 GCP

预防性抗生素预防阴道手术分娩后感染(ANODE):一项多中心随机对照试验

Prophylactic antibiotics in the prevention of infection after operative vaginal delivery (ANODE): a multicentre randomised controlled trial.
PubMed 文献 · Lancet · 2019-05-13

ANODE 试验在 27 个英国产科单位纳入 3427 名≥16 岁、≥36 周妊娠行阴道手术分娩的女性,随机接受单剂静脉阿莫西林克拉维酸或安慰剂。阿莫西林克拉维酸组确诊或疑似感染 180/1619(11%),安慰剂组 306/1606(19%),风险比 0.58(95%CI 0.49-0.69;p<0.0001)。作者认为单剂预防性抗生素有益,WHO 及其他国家指南应据此修改。

要点

  • 阴道手术分娩后单剂静脉阿莫西林克拉维酸组感染 11%(180/1619),安慰剂组 19%(306/1606)。
  • 风险比 0.58(95%CI 0.49-0.69;p<0.0001),阿莫西林克拉维酸组感染风险降低。
  • 作者认为单剂预防性抗生素有益,WHO 及其他国家指南应据此修改。

核心结论

  • 该试验显示阴道手术分娩后单剂预防性抗生素有益,WHO 及其他国家组织的指南应据此修改。

研究设计与样本

  • 在 27 个英国产科单位进行的盲法随机对照试验,纳入≥16 岁、≥36 周妊娠行阴道手术分娩的女性,随机接受单剂静脉阿莫西林克拉维酸或安慰剂(生理盐水)。
  • 2016 年 3 月 13 日至 2018 年 6 月 13 日随机分配 3427 名女性:阿莫西林克拉维酸组 1719 名,安慰剂组 1708 名;7 名退出后分别为 1715 名和 1705 名;195 名(6%)女性主要结局数据缺失。
  • 主要结局为分娩后 6 周内确诊或疑似母亲感染,定义为针对特定指征新开抗生素处方、培养确诊系统性感染或子宫内膜炎;采用意向性分析。
  • 试验注册号 ISRCTN 11166984,已停止入组。

主要发现

  • 阿莫西林克拉维酸组确诊或疑似感染 180/1619(11%),安慰剂组 306/1606(19%);风险比 0.58(95%CI 0.49-0.69;p<0.0001),阿莫西林克拉维酸组感染显著少于安慰剂组。
  • 安慰剂组 1 名女性报告皮疹;阿莫西林克拉维酸组 2 名女性报告其他过敏反应,其中 1 例报告为严重不良事件。
  • 另报告 2 例严重不良事件,均被认为与治疗无因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risk factors for maternal infection are clearly recognised, including caesarean section and operative vaginal birth. Antibiotic prophylaxis at caesarean section is widely recommended because there is clear systematic review evidence that it reduces incidence of maternal infection. Current WHO guidelines do not recommend routine antibiotic prophylaxis for women undergoing operative vaginal birth because of insufficient evidence of effectiveness. We aimed to investigate whether antibiotic prophylaxis prevented maternal infection after operative vaginal birth. METHODS: In a blinded, randomised controlled trial done at 27 UK obstetric units, women (aged ≥16 years) were allocated to receive a single dose of intravenous amoxicillin and clavulanic acid or placebo (saline) following operative vaginal birth at 36 weeks gestation or later. The primary outcome was confirmed or suspected maternal infection within 6 weeks of delivery defined by a new prescription of antibiotics for specific indications, confirmed systemic infection on culture, or endometritis. We did an intention-to-treat analysis. This trial is registered with ISRCTN, number 11166984, and is closed to accrual. FINDINGS: Between March 13, 2016, and June 13, 2018, 3427 women were randomly assigned to treatment: 1719 to amoxicillin and clavulanic acid, and 1708 to placebo. Seven women withdrew, leaving 1715 in the amoxicillin and clavulanic acid group and 1705 in the placebo groups. Primary outcome data were missing for 195 (6%) women. Significantly fewer women allocated to amoxicillin and clavulanic acid had a confirmed or suspected infection (180 [11%] of 1619) than women allocated to placebo (306 [19%] of 1606; risk ratio 0·58, 95% CI 0·49-0·69; p<0·0001). One woman in the placebo group reported a skin rash and two women in the amoxicillin and clavulanic acid reported other allergic reactions, one of which was reported as a serious adverse event. Two other serious adverse events were reported, neither was considered causally related to the treatment. INTERPRETATION: This trial shows benefit of a single dose of prophylactic antibiotic after operative vaginal birth and guidance from WHO and other national organisations should be changed to reflect this. FUNDING: NIHR Health Technology Assessment programme.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Knight M, Chiocchia V, Partlett C, et al. Prophylactic antibiotics in the prevention of infection after operative vaginal delivery (ANODE): a multicentre randomised controlled trial. Lancet. 2019. PMID: 31097213. doi:10.1016/S0140-6736(19)30773-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。